PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24701371-5 2014 Of note, the ADCC-inhibitory effect of the same IgG1 molecules was significantly reduced when NK cells expressed phenylalanine-containing FcgammaRIIIa (93% vs. 50%; P = 0.0000005). Phenylalanine 113-126 Fc gamma receptor IIIa Homo sapiens 138-150 19401346-8 2009 MDX-1401 activity with all FcgammaRIIIa polymorphic variants, including less active Phe/Phe158 and Phe/Val158 effector cells, was shown. Phenylalanine 84-87 Fc gamma receptor IIIa Homo sapiens 27-39 23871153-3 2013 The high affinity FcgammaRIIIa-158-valine (V) polymorphism is associated with more potent ADCC response than the low affinity FcgammaRIIIa-158-phenylalanine (F) polymorphism. Phenylalanine 143-156 Fc gamma receptor IIIa Homo sapiens 126-138 23379433-9 2013 In black subjects (n = 42), FcgammaRIIa-histidine/histidine homozygotes and FcgammaRIIIa-phenylalanine/valine heterozygotes were associated with high antibody responses (P = 0 0071 and 0 0275, respectively). Phenylalanine 89-102 Fc gamma receptor IIIa Homo sapiens 76-88 23680410-7 2013 With the TaqMan allelic discrimination assay, we found that 16 cases were the wild type genotype, homozygous phenylalanine (F/F), for the FCGR3a receptor, whereas two cases had the homozygous valine (V/V) polymorphism and eight cases were heterozygous with a V/F genotype. Phenylalanine 109-122 Fc gamma receptor IIIa Homo sapiens 138-144 19401346-8 2009 MDX-1401 activity with all FcgammaRIIIa polymorphic variants, including less active Phe/Phe158 and Phe/Val158 effector cells, was shown. Phenylalanine 88-91 Fc gamma receptor IIIa Homo sapiens 27-39 17875730-6 2007 By using mice transgenic for human CD16A, enhanced survival was observed due to expression of CD16A-158(phe) on monocytes and macrophages as well as on NK cells in these mice. Phenylalanine 104-107 Fc gamma receptor IIIa Homo sapiens 35-40 18179643-2 2008 Two allelic dimorphisms of these receptors, valine/phenylalanine-158 of CD16A and histidine/arginine-131 of CD32A, modulate their affinity for certain human IgG subclasses. Phenylalanine 51-64 Fc gamma receptor IIIa Homo sapiens 72-77 17875730-6 2007 By using mice transgenic for human CD16A, enhanced survival was observed due to expression of CD16A-158(phe) on monocytes and macrophages as well as on NK cells in these mice. Phenylalanine 104-107 Fc gamma receptor IIIa Homo sapiens 94-99 15037082-13 2004 The Phe to Val substitution increased FcgammaRIIIa affinity for IgG1 in an enthalpy-driven manner with the reduced dissociation rate. Phenylalanine 4-7 Fc gamma receptor IIIa Homo sapiens 38-50 16181633-1 2005 A single nucleotide polymorphism (SNP) of the FCGR3A gene results in two allotypes of Fcgamma receptor IIIA (FcgammaRIIIA) with valine (V) or phenylalanine (F) at amino acid 158. Phenylalanine 142-155 Fc gamma receptor IIIa Homo sapiens 46-52 15659493-6 2005 Polymorphisms at FcgammaRIIIA-158 were phenylalanine/phenylalanine (F/F), phenylalanine/valine (F/V), and valine/valine (V/V). Phenylalanine 39-52 Fc gamma receptor IIIa Homo sapiens 17-29 15659493-6 2005 Polymorphisms at FcgammaRIIIA-158 were phenylalanine/phenylalanine (F/F), phenylalanine/valine (F/V), and valine/valine (V/V). Phenylalanine 53-66 Fc gamma receptor IIIa Homo sapiens 17-29 15659493-6 2005 Polymorphisms at FcgammaRIIIA-158 were phenylalanine/phenylalanine (F/F), phenylalanine/valine (F/V), and valine/valine (V/V). Phenylalanine 53-66 Fc gamma receptor IIIa Homo sapiens 17-29 2531919-5 1989 Conversion of Phe to Ser in CD16-II permits expression of a PI-glycan-anchored glycoprotein, whereas conversion of Ser to Phe in CD16-I prevents PI-glycan linkage. Phenylalanine 14-17 Fc gamma receptor IIIa Homo sapiens 28-32 12799050-1 2003 A polymorphism at position 559 in the cDNA of the FCGR3A gene encoding the FcgammaRIIIa generates two allotypes with either a valine (Val) or a phenylalanine (Phe) at amino acid position 158. Phenylalanine 144-157 Fc gamma receptor IIIa Homo sapiens 50-56 12799050-1 2003 A polymorphism at position 559 in the cDNA of the FCGR3A gene encoding the FcgammaRIIIa generates two allotypes with either a valine (Val) or a phenylalanine (Phe) at amino acid position 158. Phenylalanine 144-157 Fc gamma receptor IIIa Homo sapiens 75-87 12799050-1 2003 A polymorphism at position 559 in the cDNA of the FCGR3A gene encoding the FcgammaRIIIa generates two allotypes with either a valine (Val) or a phenylalanine (Phe) at amino acid position 158. Phenylalanine 159-162 Fc gamma receptor IIIa Homo sapiens 50-56 12799050-1 2003 A polymorphism at position 559 in the cDNA of the FCGR3A gene encoding the FcgammaRIIIa generates two allotypes with either a valine (Val) or a phenylalanine (Phe) at amino acid position 158. Phenylalanine 159-162 Fc gamma receptor IIIa Homo sapiens 75-87 9242542-1 1997 We analyzed a genetic polymorphism of Fc gamma receptor IIIa (CD16) that is present on position 158 (Phe or Val) in the membrane-proximal, IgG-binding domain. Phenylalanine 101-104 Fc gamma receptor IIIa Homo sapiens 38-60 14563637-1 2004 In follicular lymphoma (FL), genomic polymorphisms corresponding to the expression of valine (V) or phenylalanine (F) at amino acid 158 of Fc gamma RIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been associated with varied responses to rituximab. Phenylalanine 100-113 Fc gamma receptor IIIa Homo sapiens 139-153 9242542-1 1997 We analyzed a genetic polymorphism of Fc gamma receptor IIIa (CD16) that is present on position 158 (Phe or Val) in the membrane-proximal, IgG-binding domain. Phenylalanine 101-104 Fc gamma receptor IIIa Homo sapiens 62-66 2531919-5 1989 Conversion of Phe to Ser in CD16-II permits expression of a PI-glycan-anchored glycoprotein, whereas conversion of Ser to Phe in CD16-I prevents PI-glycan linkage. Phenylalanine 122-125 Fc gamma receptor IIIa Homo sapiens 129-133 33081115-3 2020 CD16A, the NK receptor for antibodies, has AA158 valine or phenylalanine variants with different affinities for IgG. Phenylalanine 59-72 Fc gamma receptor IIIa Homo sapiens 0-5 24662005-3 2014 Using an ADCC inhibition assay, we show that IgG1 expressing GM 3+,1-,2- allotypes blocked all phenylalanine-expressing FcgammaRIIIa present on NK cells, resulting in total inhibition of anti-GD2 antibody-mediated ADCC of GD2-overexpressing neuroblastoma cells. Phenylalanine 95-108 Fc gamma receptor IIIa Homo sapiens 120-132 28753113-5 2018 Polymorphisms in the CD16 allele expressed on NK cells have been shown to influence the degree of ADCC of tumor cells, with the high-affinity valine (V)/V allele being responsible for more lysis than the V/phenylalanine (F) or FF allele. Phenylalanine 206-219 Fc gamma receptor IIIa Homo sapiens 21-25 26179905-3 2015 Of potential relevance are a FCGR3A dimorphism resulting in CD16A-valine/phenylalanine-158 allotypes with different IgG affinity, variations conditioning NK cell expression of CD32B or CD32C, and IgG1 H chain (IGHG1) and kappa-chain (IGKC) polymorphisms determining allotypes designated G1m and Km. Phenylalanine 73-86 Fc gamma receptor IIIa Homo sapiens 29-35 26179905-3 2015 Of potential relevance are a FCGR3A dimorphism resulting in CD16A-valine/phenylalanine-158 allotypes with different IgG affinity, variations conditioning NK cell expression of CD32B or CD32C, and IgG1 H chain (IGHG1) and kappa-chain (IGKC) polymorphisms determining allotypes designated G1m and Km. Phenylalanine 73-86 Fc gamma receptor IIIa Homo sapiens 60-65 25230857-3 2014 The clinical efficacy of ADCC is particularly impacted by a single nucleotide polymorphism (SNP) found in the gene encoding FcgammaRIIIA (FCGR3A), which generates a variable distribution of the 158 V/V, F/V or F/F CD16 allotypes (F = phenylalanine, V = valine) in the normal human population. Phenylalanine 234-247 Fc gamma receptor IIIa Homo sapiens 124-136 25230857-3 2014 The clinical efficacy of ADCC is particularly impacted by a single nucleotide polymorphism (SNP) found in the gene encoding FcgammaRIIIA (FCGR3A), which generates a variable distribution of the 158 V/V, F/V or F/F CD16 allotypes (F = phenylalanine, V = valine) in the normal human population. Phenylalanine 234-247 Fc gamma receptor IIIa Homo sapiens 138-144 25230857-3 2014 The clinical efficacy of ADCC is particularly impacted by a single nucleotide polymorphism (SNP) found in the gene encoding FcgammaRIIIA (FCGR3A), which generates a variable distribution of the 158 V/V, F/V or F/F CD16 allotypes (F = phenylalanine, V = valine) in the normal human population. Phenylalanine 234-247 Fc gamma receptor IIIa Homo sapiens 214-218 24311787-4 2014 To this end, we have identified a panel of novel Fc variants with significant binding improvement to FcgammaRIIIA (both Phe-158 and Val-158 allotypes), increased ADCC activity in vitro, and strong tumor growth inhibition in mice xenograft human tumor models. Phenylalanine 120-123 Fc gamma receptor IIIa Homo sapiens 101-113